Pfizer stock currently trades around $28.07, reflecting a 9.43x non-GAAP P/E multiple on 2026 expected earnings of $2.98 per share. That is a steep discount to the broader market’s 21.2x forward multiple.
The stock has returned 16.1% over the past year, putting it modestly ahead of the S&P 500 in 2026. But zoom out five years and the picture changes. PFE is still down 21.5% over that stretch, meaning longer-term holders are still waiting to get back to even.
The revenue story is not pretty right now. Pfizer’s updated 2026 guidance of $60.5–$62.5 billion is roughly 39% below its 2022 peak of $100.3 billion, when COVID vaccine and treatment sales were booming.
Post-pandemic demand for COVID products has fallen sharply. Patent expirations on drugs like Xeljanz are adding further pressure, with analysts projecting EPS to dip slightly from $2.98 in 2026 to $2.90 in 2027 as more exclusivity periods end.
Despite all of that, Pfizer is spending more, not less, on research. R&D spending rose about 13% in H1 2026, even as the company braces for a roughly 2% revenue decline this year.
The bet is on a pipeline payoff. Pfizer is targeting high single-digit compound revenue growth after 2028, driven by oncology, mRNA platforms, and cancer antibody-drug conjugate therapies. The Lyme disease vaccine candidate has also drawn attention.
Manufacturing optimization and cost realignment programs are running in parallel with the R&D push. Pfizer is targeting an additional $2.7 billion in cuts between 2027 and 2029, bringing total targeted net savings to approximately $9.7 billion through 2029.
If the company hits both its revenue ambitions and cost targets, earnings are expected to pick up materially starting in 2029.
While investors wait, the dividend is doing some of the work. Pfizer pays a quarterly dividend of $0.43, translating to an annual yield of about 6.13%. With a payout ratio of roughly 0.58x against expected 2026 earnings, there is a reasonable buffer before that dividend comes under pressure.
Not everyone agrees the stock is cheap. Simply Wall St flags a GAAP P/E of 36.9x, above the pharmaceutical industry average of 16.8x and its own tailored fair multiple of 24.7x. That reading suggests the recent rally may have already priced in some optimism.
The two analyses are not necessarily contradictory. The non-GAAP multiple of 9.43x strips out items like acquisition-related charges, which are considerable given Pfizer’s recent deal activity.
On Wall Street, PFE carries a Moderate Buy consensus from eight Buy, 12 Hold, and one Sell rating over the past three months. The average price target sits at $28.46, implying about 1.37% upside from current levels.
The post Pfizer (PFE) Stock: Wall Street Says Buy, But the Valuation Debate Is Real appeared first on CoinCentral.
